Composition and methods for anti-tnfr2 antibodies

Abstract

The composition of anti-TNFR2 antibodies are provided, as well as methods of their preparation and use. This includes methods for treating disorders associated with TNFα and/or TNFR2, such as cancer.

What is claimed is: 
     
         1 . A humanized anti-TNFα Receptor 2 (anti-TNFR2) antibody that blocks TNFα binding to TNFR2, wherein the anti-TNFR2 antibody comprises a set of three heavy chain complementary determining regions (HCDRs) and three light chain complementary determining regions (LCDRs), wherein the set of three HCDRs and three LCDRs are selected from the group consisting of:
 (a) SEQ ID NOs: 46-48 (HCDRs) and SEQ ID NOs: 49-51 (LCDRs); 
 (b) SEQ ID NOs: 46-48 (HCDRs) and SEQ ID NOs: 52-54 (LCDRs); 
 (c) SEQ ID NOs: 55-57 (HCDRs) and SEQ ID NOs: 58-60 (LCDRs); and 
 (d) SEQ ID NOs: 55-57 (HCDRs) and SEQ ID NOs: 61-63 (LCDRs). 
 
     
     
         2 . The humanized anti-TNFR2 antibody of  claim 1 , wherein the set of three HCDRs comprises SEQ ID NOs: 46-48 and wherein the set of three LCDRs comprises SEQ ID NOs: 49-51. 
     
     
         3 . The humanized anti-TNFR2 antibody of  claim 1 , wherein the set of three HCDRs comprises SEQ ID NOs: 46-48 and wherein the set of three LCDRs comprises SEQ ID NOs: 52-54. 
     
     
         4 . The humanized anti-TNFR2 antibody of  claim 1 , wherein the set of three HCDRs comprises SEQ ID NOs: 55-57 and wherein the set of three LCDRs comprises SEQ ID NOs: 58-60. 
     
     
         5 . The humanized anti-TNFR2 antibody of  claim 1 , wherein the set of three HCDRs comprises SEQ ID NOs: 55-57 and wherein the set of three LCDRs comprises SEQ ID NOs: 61-63. 
     
     
         6 . The humanized anti-TNFR2 antibody of  claim 1 , wherein said anti-TNFR2 antibody comprises a human variable region heavy chain (V H ) sequence comprising three heavy chain complementary determining regions (HCDRs) derived from a non-human sequence and a human variable region light chain (V L ) comprising three light chain complementary determining regions (LCDRs) derived from a non-human source. 
     
     
         7 . The humanized anti-TNFR2 antibody of  claim 6 , wherein said anti-TNFR2 antibody comprises a variable region heavy chain (V H ) comprising three heavy chain complementary determining regions (HCDRs) and a variable region light chain (V L ) comprising three light chain complementary determining regions (LCDRs), wherein the V H  comprises an amino acid sequence having at least 60% sequence identity to the amino acid sequence of SEQ ID NO: 66 or 68, and the V L  comprises an amino acid sequence having at least 60% sequence identity to the amino acid sequence of SEQ ID NO: 69. 
     
     
         8 . The humanized anti-TNFR2 antibody of  claim 1 , wherein said anti-TNFR2 antibody comprises a human IgG1 Fc domain. 
     
     
         9 . The humanized anti-TNFR2 antibody of  claim 8 , wherein said human IgG1 Fc domain is null for binding to an Fcγ receptor. 
     
     
         10 . A pharmacological composition comprising the humanized anti-TNFR2 antibody that blocks TNFα binding to TNFR2 of  claim 1 , and a pharmaceutically acceptable carrier. 
     
     
         11 . A method of eliciting an immune response against a tumor in a patient, comprising administering to the patient the pharmaceutical composition of  claim 10 .